Summary Hexadecafluorinated zinc phthalocyanine (ZnPcF,6), an analogue of zinc phthalocyanine (ZnPc) in which all hydrogen atoms have been substituted by fluorine, was prepared as a single isomeric product via the condensation of tetrafluorophthalonitrile with zinc acetate. Fluorination renders the ZnPc soluble in most common solvents. The photodynamic properties and pharmacokinetics of the ZnPcF,6 were evaluated in EMT-6 tumour-bearing Balb/c mice using 65Zn-radiolabelled analogues. Both dyes, administered i.v. at fLmol kg-' as Cremophor emulsions, revealed good tumour uptake [approximately 8-9 per cent of the injected dose per g tissue (%ID g-')] at 24 h post injection (p.i.), with the fluorinated dye reaching higher concentrations (approximately 11%ID g -') at 48 h p.i. and subsequently higher tumour -blood ratios due to rapid blood clearance. ZnPcF,6 at a dose of 5 pmol kg-' (4.3 mg kg-') induced complete tumour regression after phototherapy (24 h p.i., 650 -700 nm band, 360 J cm-2, 200 mW cm -'). At a dose of 2 fimol kg-' and phototherapy at 24 h p.i., the tumour volume doubling time increased to 11 days vs 6 days for the control tumours. A similar tumour growth delay was observed when phototherapy was conducted at 48 h or 72 h after dye injection implying that tumour response correlates with tumour dye concentrations rather than serum concentrations. As a result of its low solubility, the administered dose of ZnPc was limited to 1 fimol kg-' and at this drug level significant tumour response was only observed when the dye was solubilised as the pyridinium salt. Isolation of the neoplastic cells after in vivo dye administration and in vitro exposure to red light followed by a colony formation assay showed that the ZnPcF,6 exhibited a 1-2 order of magnitude higher potential for direct cell killing as compared with Photofrin and about a five times lower efficiency than ZnPc. However, all three photosensitisers induced complete occlusion of tumour vasculature immediately after PDT, suggesting that tumour regression mainly resulted from vascular stasis. The ZnPcF,6 offers several advantages over ZnPc for clinical applications, including improved solubility in most solvents, resulting in facilitated drug formation, favourable pharmacokinetics as well as the potential use in fluorine magnetic resonance (F-MR) imaging.
Phthalocyanines (Pcs) are among the various classes of dyes that have been proposed as sensitisers to supersede haematoporphyrin derivative (Photofrin II), currently used for clinical photodynamic therapy (PDT) of cancer (van Lier, 1990; Rosenthal, 1991) . This is due to the superior molar absorptivity of these compounds (a> I05 M-1 cm-' when fully monomerised), at wavelengths permitting greater penetration of light in normal tissues (typically 670-680 nm), when compared with Photofrin (e 10' M-1cm-1 at 630 nm). As a result of the extremely low solubility of unsubstituted Pcs in most common solvents, much of the research into the use of Pcs as photodynamic sensitisers has concentrated on sulphonated derivatives, which are soluble in polar solvents (e.g. water and/or alcohol). Methods for synthesis of sulphonated Pcs, however, often yield complex mixtures composed of different levels of substitution and regioisomers (Ali et al., 1988) .
Among the non-substituted Pcs, zinc phthalocyanine (ZnPc) has been investigated as a possible second generation PDT sensitiser (Ginevra et al., 1990; Reddi et al., 1990) . The material is highly insoluble in most common solvents and a proprietary liposomal formulation has been advanced for clinical trials (Schieweck et al., 1994) . To overcome such solubility problems we proposed the fluorinated analogue of ZnPc as a sensitiser for PDT (Boyle and van Lier, 1991) .
Hexadecafluorinated zinc phthalocyanine (ZnPcF, 6) ( Figure   1 ) can be conveniently synthesised, in one step, from commercially available starting materials, yielding a symmetrical product without isomers. Fluorine Lier, 1991) . The crude compound was purified by suspension in aqueous hydrogen chloride (2 M) followed by filtration, washing of the residue with ethanol, and extraction into acetone. Finally the product was passed through a short column of silica gel eluting with acetone. Removal of the solvent gave ZnPcF,6 in 50-60% yield (mol. Animal Care and an in-house ethics committee. The animals were allowed free access to water and food throughout the course of the experiments. Mice had one tumour transplanted into the right hind thigh by intradermal injection of 2 x 105 EMT-6 cells suspended in 0.05 ml of Waymouth's medium (Gibco). Animals were used 6-9 days p.i. when tumours had reached a diameter of 3-5 mm with an average volume of 16.6 mm3 (s.e.m. 0.8).
[65Zn]ZnPcF,6 and [65Zn]-ZnPc (0.2 ml; 25 nmol; 13 nCi) were injected i.v. via the caudal vein, corresponding to a drug dose of 1.0 ytmol kg-'.
At appropriate time intervals animals were sacrificed, blood was collected and tissues of interest were removed, washed with 0.1 54 M aqueous sodium chloride, blotted dry and placed in pre-weighed tubes. Tubes were sealed to avoid loss of moisture. Radioactivity of the samples, together with an aliquot of the injected preparation, were counted, and activities were calculated and expressed as the percentage of the injected dose per gram of tissue (%ID g-'). For excretion studies mice were placed in metabolic cages and faeces and urine were collected and pooled.
Photodynamic therapy Mice were prepared as for biodistribution studies (see above) except that two tumours were grown, one on each hind thigh. The right tumour was irradiated while the left (control) tumour was shielded from light. Animals were injected via the tail vein, with 5.0, 2.0 or 1.0 timol kg-' ZnPcF,6 formulated in Cremophor, as described above. Because of its insolubility, ZnPc was studied at I ytmol kg-' only. After 24, 48 or 72 h the tumour on the right thigh was irradiated with an 8 mm circular light beam of red light (650-700 nm; 360 J cm-2 at a fluence rate of 200 mW cm-2) delivered by a 1000 W xenon lamp fitted with 10 cm water filter, and LS700 and LL650 (Corion) filters. In the case of Photofrin II a band of 600-650 nm was used at the same fluence, and fluence rate, using LS650 and LL600 (Corion) filters. Tumour response was assessed qualitatively and followed from initial necrosis (within 48 h), to cure and for a followup period of 30 days. Tumour cure was defined as necrosis of the tumour mass within 48 h after irradiation, followed by regrowth of normal tissue in the treatment area and no recurrence of the neoplasm up to 30 days post-irradiation. For %ID g '), and subsequently (t>24 h) low blood concentrations of the ZnPcF,6. Tumour concentrations together with tumor-blood, tumour-skin and tumour-muscle ratios are presented in Figure 4 . The ZnPc reached a maximum concentration of 8%ID g-' (2 nmol g-') at 24 h p.i., while the ZnPcF,6 reached somewhat higher levels, e.g. 9, 11 and 8.5%ID g-', at 24, 48 and 72 h p.i. respectively (Figure 4 ).
The amounts of both dyes in muscle and skin was low, resulting in favourable tumour-tissue ratios. The rapid blood clearance of the ZnPcF,6 resulted in significantly higher tumour-blood ratios at longer periods p.i. than those observed with the ZnPc (Figure 4 ). days for the control tumors (n = 7). PDT at 48 h p.i. gave a doubling time of 11 (± 1) days vs 8 (± 1) days for the controls (n = 8) and at 72 h p.i. the doubling time of the treated tumors was 12 ( ± 1) days vs 8 ( ± 0.5) days for the control tumours (n = 9). Although doubling time varied only slightly with the delay in time interval between dye administration and PDT, none of the animals in the 24 h group showed tumour cure, whereas 25% of the animals in the 48 h and 72 h group were tumour free 21 days post treatment. Owing to its low solubility, the unsubstituted ZnPc can only be formulated to higher dye concentration when initially dissolved in pyridine. Cremophor emulsions derived from such solutions still contain traces of pyridine, which are coordinated to the axial ligands of the central metal ion of ZnPc, favouring the photodynamic potential of the ZnPc. This formulation induced complete tumour regression at 2 ,tmol kg-' (1.2mg kg-') following PDT at 24 h p.i. with complete vascular stasis in the tumour immediately after illumination. Since pyridine is not accepted for clinical drug formulation we also used 1-methyl-2-pyrrolidinone to initially dissolve the ZnPc to yield concentrations of ZnPc in Cremophor suitable for a maximum dye administration of 1 ytmol kg-'. However, at these dose levels the ZnPc Cremophor emulsions did not induce a significant tumour response following PDT (24 h p.i.).
In vitro phototherapy after in vivo dye administration revealed different levels of photosensitivity of the tumour cells after the different treatment protocols. The ZnPc (pyridinium complex, Cremophor emulsion) had the highest potential to inflict direct cell kill during PDT since a five times lower in vivo dose, as compared with ZnPcF,6 (Cremophor emulsion), resulted in similar in vitro tumour cell photosensitivity ( Figure 5 ). Thus with ZnPc we obtained an ex vivo LD90 = 50 J cm-2 (24 h p.i. of 2 jtmol kg-'), while with ZnPcF,6 an ex vivo LD90 = 45 J cm-2 (24 h p.i. of 10[Lmolkg-') was observed ( Figure 5 ). In agreement with earlier reports (Henderson and Bellnier, 1989) , the direct cell killing potential of Photofrin was found to be extremely low. Only 10% cell killing was observed with a fluence of 50 J cm-2 (24 h p.i. of 10mg kg-'). Variations in the ex vivo LD90 of the ZnPcF,6 paralleled the in vivo dye uptake pattern by the tumour, e.g. the lowest LD90 = 45 J cm-2 was observed at 48 h p.i. when tumour dye levels were at a maximum, and identical LD90 = 70 J cm-2 were recorded at 24 and 72h p.i., when tumour dye concentrations were lower, but similar (Figures 4 and 5) .
Discussion
In this study we have evaluated the effect of fluorination on the pharmacokinetic and photodynamic properties of ZnPc. The biodistribution and PDT efficacy of ZnPc have previously been studied extensively using standard liposomal preparations (Reddi et al., 1987 Milanesi et al., 1990) and ZnPc encapsulated in a proprietary liposomal preparation has been proposed for clinical trials (Schieweck et al., 1994) . Our tumour uptake and blood clearance data of the [65Zn]ZnPc in CRM-emulsions are similar to the earlier reported finding with liposomal ZnPc preparations (Reddi et al., 1987) . Partition between the carrier and various serum proteins probably determines the fate of the dyes, suggesting that similar blood transport and tumour uptake mechanism are involved, regardless of the carrier. Low density lipoproteins (LDLs) have been implicated in the transport of hydrophobic drugs and their preferential interaction with endothelial and neoplastic cells of tumour tissue may, at least in part, explain tumour selectivity (Goldstein et al., 1979; Netland et al., 1988) .
Increased solubility of the ZnPcF,6 vs ZnPc in various common solvents allows for drug formulation in a wider selection of vehicles. Thus in addition to CRM, we recently showed that ZnPcF,6 can readily be formulated in biode- gradable polyethylene glycol-coated poly(lactic acid) nanoparticles (PEG-coated PLA NP), resulting in advantageous biodistribution and excretion pattern for PDT applications (Allemann et al., 1995) . Topical application of ZnPcF16 formulated in CRM also induced a good tumour response in the EMT-6 tumour model, whereas ZnPc was inactive under these conditions (Margaron et al., 1992) . The use of y-emitting 65Zn for quantification of the dyes greatly facilitated the biodistribution studies since dye extraction was circumvented and problems with fluorescence quenching were eliminated. Zn(II) is strongly chelated within the Pc macrocycle cavity and no evidence was found for in vivo dissociation of the 65Zn from the dye complexes. The procedure however does not distinguish between concentrations of photoactive-monomeric and inactive-aggregated forms of the dye, which could result in overestimation of the photodynamic potential based on 65Zn concentrations only. Also, distribution patterns within the tumour compartment are not visualised in this manner. It is obvious that dye localisation at sensitive cellular components is more important for PDT efficacy than high overall tissue concentrations. Tumour response with ZnPcF16-PDT appears, however, directly related to tumour dye levels rather than blood concentration. This is demonstrated by comparing actual tissue concentrations and tumour-blood ratios of the ZnPcF16 (Figure 4 ) with tumour response following PDT at 24 h, 48 h and 72 h p.i. The tumour volume doubling times of the treated tumours are similar over these time intervals (11-12 days vs 6-8 days for control tumours), paralleling the stable tumour dye concentrations (9-10%ID g-') over the 24-72 h p.i. time interval. In contrast, blood ZnPcF16 concentrations decrease rapidly over the same time interval, resulting in a large increase in tumor-blood ratios between 24 h, 48 h and 72 h p.i. (Figure  4 ). The faster blood clearance of the ZnPcF16 as compared with ZnPc should be advantageous for a clinical setting since the presence of photosensitiser in the serum has been correlated with prolonged cutaneous photosensitivity, which is considered a major side-effect of PDT (Zalar et al., 1977) .
A correlation between in vivo dye levels and ex vivo tumour cell photosensitivity appears to hold in regard to the overall change in the dye concentration in the tumour over time. Thus in the case of the ZnPcF16, tumour concentrations vary from approximately 9%ID g-1 at 24 and 72 h p.i., to 11 %ID g-' at 48 h p.i. The ex vivo cell photosensitivity follows a similar pattern requiring approximately 70 J cm2 for 90% cell kill at 24 and 72 h, vs approximately 45 J cm2 at 48 h ( Figure 5 ). These apparent variations in cell uptake will probably not be restricted to tumour cells only. Differences in uptake by endothelial cells and macrophages, between the ZnPcF16 and ZnPc, also could explain their relative PDT efficacy. Damage to these cells will trigger the release of vasoactive biomolecules, which induce restriction of the small vessels in the affected tissue, resulting in local shut-down of the blood circulation (Henderson, 1990) . In this regard it should be noted that immediately after PDT with all three dyes, vascular stasis is extensive, as demonstrated by exclusion of fluorescein from the blood flow in the tumour area. Such a pattern is characteristic of an indirect cell damage mechanism and the resulting tumour regression has been attributed to oxygen deprivation following vascular stasis (Henderson, 1990 
